A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT00619099
- Locations
- 🇺🇸
Landmark Medical Center, Woonsocket, Rhode Island, United States
🇺🇸Sarah Cannon Research, Nashville, Tennessee, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 604
- Registration Number
- NCT00603291
- Locations
- 🇺🇸
Arena Pharmaceuticals, Inc., San Diego, California, United States
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 4008
- Registration Number
- NCT00603902
- Locations
- 🇺🇸
Arena Pharmaceuticals, Inc., San Diego, California, United States
Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT00592774
- Locations
- 🇺🇸
Pain and Rehabilitation Clinic of Chicago, Chicago, Illinois, United States
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT00592904
The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT00571064
- Locations
- 🇺🇸
Senior Care, Birmingham, Alabama, United States
🇺🇸21st Century Neurology, Phoenix, Arizona, United States
🇺🇸South Coast Clinical Trials, Anaheim, California, United States
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT00570128
- Locations
- 🇺🇸
Community Research Foundation, Miami, Florida, United States
🇺🇸Miami Children's Hospital, Brain Institute, Miami, Florida, United States
🇺🇸UCSD Pediatric Pharmacology Research Unit, San Diego, California, United States
Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT00566254
Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00566462
- Locations
- 🇺🇸
inVentiv, The Woodlands, Texas, United States
🇺🇸Kenneth Marek, New Haven, Connecticut, United States
🇺🇸Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 915
- Registration Number
- NCT00566501
- Locations
- 🇺🇸
Apex Research Institute, Santa Ana, California, United States